Risk-guided plan to prevent heart failure after cancer treatment
Part of Heart & circulation clinical trials.
This trial tests whether a personalized, risk-based heart care plan can help prevent heart failure in people who had certain cancer treatments. It focuses on monitoring and guiding treatment, using heart ultrasound results and other health factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had cancer more than 10 years ago
- You previously received one of these: anthracycline chemotherapy, trastuzumab for HER2-positive breast cancer, certain cancer pills like sunitinib, or left-chest radiation
- Your heart pumping strength on an echo (ultrasound) is not below 50%
- You do not have more than moderate heart valve problems
- You have not had heart failure symptoms that are worse than mild (NYHA greater than 2 means not eligible)
- You can safely take the usual heart medicines (beta blockers and ACE inhibitors/ARBs) and you can attend heart scans for clear results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This feasibility study looks at how to support decision-making about preventing heart problems in adults after a cancer diagnosis. It may help by making it easier to assess cardiovascular risk and start appropriate heart-protection planning earlier.
This study tests whether a structured exercise and heart-health rehabilitation program can improve heart function and reduce heart problems in people who have finished cancer treatment or are on stable cancer therapy. If you've had cancer treatment that might affect your heart, this program could help you recover better and live healthier.
This trial tests a multidisciplinary care approach aimed at helping people with high risk for heart failure get diagnosed earlier. It may help you catch heart failure sooner if it starts, so treatment can begin earlier.
This study tests a heart medication (sacubitril/valsartan) in young cancer survivors whose hearts were weakened by anthracycline chemotherapy but are not yet having heart failure symptoms. It aims to see if the drug can improve heart function and prevent future problems.
This trial tests a structured lifestyle and exercise change program for young people who finished cancer treatment and have signs of early heart weakness. The goal is to improve heart health and lower the chance of heart failure later.
This trial tests whether it is safe to stop taking heart failure medications in people who developed heart weakness after cancer treatment but whose heart function has since recovered. It aims to see if stopping these drugs leads to any worsening of heart health.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.